Lumosa Therapeutics Co., Ltd.
6535
Rank in Stocks
#13700
Lumosa Therapeutics Co., Ltd. is a clinical-stage pharmaceutical company,... Lumosa Therapeutics Co., Ltd. is a clinical-stage pharmaceutical company, headquartered in Taiwan, focused on developing innovative therapies for neurological and oncological diseases. Its most advanced product, LT-1001, an injectable analgesic, has completed Phase III clinical trials for the management of severe post-operative pain. The company's pipeline also includes LT3001, currently in Phase II for treating acute ischemic stroke; LT5001, which has finished Phase Ib trials for uremic pruritus; and LT2003, an oncology drug candidate in its preclinical development stage. Founded in 2000, Lumosa Therapeutics maintains its operational base in Taipei.
Share Price
$2.21
Last synced: 2026-11-10
Market Cap
$370.16M
Change (1 day)
1.40%
Change (1 year)
-63.37%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Lumosa Therapeutics Co., Ltd. (6535)
Category
Healthcare
EPS for Lumosa Therapeutics Co., Ltd. (6535)
EPS as of June 2026 TTM: $-0.07
According to Lumosa Therapeutics Co., Ltd.'s latest financial reports, its current EPS (TTM) is $-0.07. At the end of 2025 the company had an EPS of $-0.07, an increase over its 2024 EPS of $-0.08.
EPS history for Lumosa Therapeutics Co., Ltd. from 2013 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.07 | -1.71% |
| 2025 | $-0.07 | -17.86% |
| 2024 | $-0.08 | 65.97% |
| 2023 | $-0.05 | -51.66% |
| 2022 | $-0.10 | -529.00% |
| 2021 | $0.02 | -124.39% |
| 2020 | $-0.09 | 38.25% |
| 2019 | $-0.07 | 310.18% |
| 2018 | $-0.02 | -77.79% |
| 2017 | $-0.08 | -6.93% |
| 2016 | $-0.08 | -5.39% |
| 2015 | $-0.09 | 11.49% |
| 2014 | $-0.08 | 98.96% |
| 2013 | $-0.04 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -22,861.63% |
US
|
|
| $-7.07 | 10,176.16% |
US
|
|
| $-5.29 | 7,588.95% |
AU
|
|
| $12.88 | -18,821.08% |
BE
|
|
| $21.56 | -31,437.21% |
NL
|
Questions about Lumosa Therapeutics Co., Ltd.'s earnings per share (EPS)
What is Lumosa Therapeutics Co., Ltd.'s earnings per share (EPS)?
Lumosa Therapeutics Co., Ltd.'s earnings per share (EPS) over the last twelve months is $-0.07, as of Jun 2026.
What was Lumosa Therapeutics Co., Ltd.'s earnings per share (EPS) in 2025?
In 2025, Lumosa Therapeutics Co., Ltd.'s earnings per share (EPS) was $-0.07, compared with $-0.08 in 2024.
How has Lumosa Therapeutics Co., Ltd.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Lumosa Therapeutics Co., Ltd.'s earnings per share (EPS) was highest in 2021 ($0.02) and lowest in 2022 ($-0.10).
How does Lumosa Therapeutics Co., Ltd.'s earnings per share (EPS) compare with similar companies?
Lumosa Therapeutics Co., Ltd.'s earnings per share (EPS) ($-0.07) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.